Journal
TRENDS IN IMMUNOLOGY
Volume 39, Issue 3, Pages 173-184Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2017.12.005
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research [MT-14429, MOP-82906, FDN-143338]
- Canadian Cancer Society Research Institute [018114]
- International Development Research Centre [108403]
Ask authors/readers for more resources
Inhibitory immune checkpoint blockade has been one of the most significant advances in anticancer therapy of the past decade. Research so far has largely focused on improving adaptive immune functions, but recent studies have indicated that the signal-regulatory protein (SIRP)alpha-CD47 pathway, a phagocytosis checkpoint in macrophages and other innate immune cells, may be an interesting therapeutic target. Here, we summarize current knowledge about SIRP alpha-CD47 blockade, and highlight key issues for future investigations. These include the targeting of prophagocytic receptors (Fc receptors or otherwise) to complement SIRP alpha-CD47 blockade, the understanding of constraints on phagocytosis other than the SIRP alpha-CD47 checkpoint and the contribution of immune cells other than macrophages. A better understanding of how SIRP alpha-CD47 blockade works may aid in identifying patients suitable for this therapy, avoiding potential toxicities and designing optimal combination therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available